ResearcherMayo Clinic in FloridaActive in the last 2 years
Ahmed Elhariri
Matched on ORCID iD 0000-0002-3715-4842; OpenAlex author ID A5087752235. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 32
2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 4
- Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
- Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival. Co-author DOI 10.21037/jgo-2025-100↗
- Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1007/s11523-024-01088-3↗
- Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. Co-author DOI 10.5306/wjco.v14.i8.285↗
Closest collaborators
The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mitesh J. Borad · 3 shared papers, 2023–2025 · strength 0.63
- Paper Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a p… DOI 10.21037/jgo-2025-100↗
- Paper Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer. DOI 10.1007/s11523-024-01088-3↗
- Paper Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. DOI 10.5306/wjco.v14.i8.285↗
- Hani M. Babiker · 3 shared papers, 2023–2025 · strength 0.63
- Paper Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a p… DOI 10.21037/jgo-2025-100↗
- Paper Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer. DOI 10.1007/s11523-024-01088-3↗
- Paper Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. DOI 10.5306/wjco.v14.i8.285↗
- Douaa Albelal · 2 shared papers, 2024–2025 · strength 0.47
- Himil J Mahadevia · 2 shared papers, 2024–2025 · strength 0.47
- Umair Majeed · 2 shared papers, 2023–2025 · strength 0.40
- Nguyen H. Tran · 1 shared paper, 2025 · strength 0.24
- Michael S. Rutenberg · 1 shared paper, 2025 · strength 0.24
- Michael James Overman · 1 shared paper, 2026 · strength 0.19
- Matthew H. G. Katz · 1 shared paper, 2026 · strength 0.19
- Abdelrahman M.G. Yousef · 1 shared paper, 2026 · strength 0.19
- Jason A. Willis · 1 shared paper, 2026 · strength 0.19
- Saikat Chowdhury · 1 shared paper, 2026 · strength 0.19
- Robert A. Wolff · 1 shared paper, 2026 · strength 0.19
- Naruhiko Ikoma · 1 shared paper, 2026 · strength 0.19
- Mahmoud Yousef · 1 shared paper, 2026 · strength 0.19
- Haoqiang Ying · 1 shared paper, 2026 · strength 0.19
- Rebecca Anne Snyder · 1 shared paper, 2026 · strength 0.19
- Ethan Bernard Ludmir · 1 shared paper, 2026 · strength 0.19
- Anirban Maitra · 1 shared paper, 2026 · strength 0.19
- Eugene Jon Koay · 1 shared paper, 2026 · strength 0.19
- Brandon George Smaglo · 1 shared paper, 2026 · strength 0.19
- Dan Zhao · 1 shared paper, 2026 · strength 0.19
- Huamin Wang · 1 shared paper, 2026 · strength 0.19
- Shubham Pant · 1 shared paper, 2026 · strength 0.19
- Ryan W. Huey · 1 shared paper, 2026 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.